| Cynthia Jeanne Cornelius, DPM | |
|
246 Federal Rd, Ste C21, Brookfield, CT 06804-2647 | |
| (203) 740-8637 | |
| (203) 740-8750 |
| Full Name | Cynthia Jeanne Cornelius |
|---|---|
| Gender | Female |
| Speciality | Podiatry |
| Experience | 35 Years |
| Location | 246 Federal Rd, Brookfield, Connecticut |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1235287079 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 213E00000X | Podiatrist | N004611 (New York) | Primary |
| Provider Name | Danbury Hospital |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1548293343 PECOS PAC ID: 1557273935 Enrollment ID: O20031104000476 |
News Archive
Claimsnet.com inc., a leading provider of Internet-based claims processing solutions for the healthcare industry, today reported its results for the second quarter of 2012, which ended June 30, 2012.
Researchers at UCLA, Duke University and other collaborating institutions have developed a biomaterial that may significantly reduce scar formation after wounding, leading to more effective skin healing.
More individualized therapy and better supportive care helped push the survival for children with acute myeloid leukemia (AML) to 71 percent three years after diagnosis, according to new research led by St. Jude Children's Research Hospital investigators and reported in the medical journal The Lancet Oncology. The survival rate of 71 percent is 20 percent better than previously reported U.S. rates and is similar to the success achieved in a 2009 Japanese study, said Jeffrey Rubnitz, M.D., Ph.D., a member of the St. Jude Oncology department.
The drug ceritinib (trade name: Zykadia) has been approved since May 2015 for the treatment of adults with non-small cell lung cancer (NSCLC). It is an option when certain changes in the cancer cells (anaplastic lymphoma kinase-positive) stimulate tumour growth and patients have already been pretreated with crizotinib.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Cynthia Jeanne Cornelius, DPM 246 Federal Rd, Ste C21, Brookfield, CT 06804-2647 Ph: (203) 740-8637 | Cynthia Jeanne Cornelius, DPM 246 Federal Rd, Ste C21, Brookfield, CT 06804-2647 Ph: (203) 740-8637 |
News Archive
Claimsnet.com inc., a leading provider of Internet-based claims processing solutions for the healthcare industry, today reported its results for the second quarter of 2012, which ended June 30, 2012.
Researchers at UCLA, Duke University and other collaborating institutions have developed a biomaterial that may significantly reduce scar formation after wounding, leading to more effective skin healing.
More individualized therapy and better supportive care helped push the survival for children with acute myeloid leukemia (AML) to 71 percent three years after diagnosis, according to new research led by St. Jude Children's Research Hospital investigators and reported in the medical journal The Lancet Oncology. The survival rate of 71 percent is 20 percent better than previously reported U.S. rates and is similar to the success achieved in a 2009 Japanese study, said Jeffrey Rubnitz, M.D., Ph.D., a member of the St. Jude Oncology department.
The drug ceritinib (trade name: Zykadia) has been approved since May 2015 for the treatment of adults with non-small cell lung cancer (NSCLC). It is an option when certain changes in the cancer cells (anaplastic lymphoma kinase-positive) stimulate tumour growth and patients have already been pretreated with crizotinib.
› Verified 2 days ago
Brookfield Podiatry Podiatrist Medicare: Not Enrolled in Medicare Practice Location: 246 Federal Rd, Suite C-21, Brookfield, CT 06804 Phone: 203-740-8637 Fax: 203-740-8750 |